ICR cancer drug programme aims to deliver a step change in cancer treatment

The world’s first ‘Darwinian’ cancer drug programme was launched by the Institute of Cancer Research (ICR), and aims to deliver a step change in cancer treatment. The programme will be run from the ICR’s £75 million state-of-the-art Centre for Cancer Drug Discovery in London. The new cancer drug programme will harness evolutionary science to tackle […]

read more

Clinical significance of PD-1 and PD-L1 receptors in kidney cancer

A recent study, published in Cancer Science this month, suggests that PD-1 and PD-L1 expression by immune cells in kidney cancer tumours is involved in resistance to treatment, i.e. part of the reason why tumours stop responding to treatment. The researchers suggest that treatment with immune checkpoint inhibitors may be a promising therapeutic strategy for […]

read more

The hunt for a kidney cancer biomarker reveals two more potential candidates

As the hunt for a reliable biomarker for renal cell carcinoma (RCC) continues, two further studies this month reveal potential candidates. The first study, published in Targeted Oncology, describes serum (blood) α1-globulin as an independent predictor (prognostic factor) of overall survival and progression-free survival in metastatic RCC, and is correlated with a high amount of […]

read more

Scientists discover the mechanism for resistance to immunotherapy treatment

Scientists from the Dana-Farber Cancer Institute in Boston, USA, have discovered a genetic mechanism in kidney cancer and melanoma cells that explains the mechanism for resistance to immunotherapy drugs called checkpoint inhibitors. This might help to explain why some people respond to immunotherapy, while others do not. The research is published in two articles in […]

read more

Researchers discover the mechanism that causes kidney cancer to recur

New research published in the journal Nature Communications this month has identified the molecular mechanism that causes kidney cancer to resist drug treatment and recur. Researchers from The University of Texas Health Science Center at San Antonio and US Department of Veterans Affairs identified the presence of an enzyme called NOX4 within the mitochondria (energy factories) of kidney […]

read more

Researchers discover a mechanism that reverses TKI drug resistance

Researchers from the Breast Cancer Clinical Research Unit at the Spanish National Cancer Research Centre (CNIO) have discovered a resistance mechanism to antiangiogenic drugs, a class of drugs commonly used to treat cancer. They published their findings in the journal Cell Reports recently, where they describe the resistance mechanism to these compounds and, more importantly, a way to […]

read more
Showing all 6 results